Isotype | IgG |
ProductType | BlockingPeptide |
Units | 50µg |
Host | Rabbit |
Speciesreactivity | Human |
Application | WesternBlotting |
BackgroundMutationsinelongationofverylong-chainfattyacid-4(ELOVL4)areassociatedwithautosomaldominantStargardt-likemaculardegeneration(STGD3),withafivebase-pair(5bp)deletionmutationresultinginthelossof51carboxy-terminalaminoacidsandtruncationoftheprotein.Elovl4isexpressedintheretinaandonlyalimitednumberofmammalianothertissues,includingskin,withunknownfunction.Inamousemodelwiththe5-bpdeletionintheElovl4gene,miceintheheterozygousstate(Elovl4(+/del))demonstrateprogressivephotoreceptordegeneration.Homozygousmice(Elovl4(del/del))displayscaly,wrinkledskin,haveseverelycompromisedepidermalpermeABIlitybarrierfunction,anddiewithinafewhoursafterbirth.LipidanalysesofepidermisfromElovl4(del/del)miceshowadecreaseinverylong-chainfattyacids(VLFAs)inboththeceramide/glucosylceramideandthefreefatty-acidfractions.ELOVL4isrequiredforgeneratingVLFAcriticalforepidermalbarrierfunction.
Synonyms:Elongationofverylongchainfattyacidsprotein4,ELOV4
Source
Immunogen:SyntheticpeptdidederivedfromthehumanELOV4protein
Product
ProductForm:Unconjugated
Formulation:Providedassolutioninphosphatebufferedsalinewith0.08%sodiumazide
Concentration:Seevialforconcentration
ApplicationsForusewithELOV4polyclonalantibodies(Cat.No.X2087P&X2381P).
FunctionalAnalysis:WesternBlotting
PositiveControl:Expressedintheretinaandatmuchlowerlevelinthebrain.
StorageProductshouldbestoredat-20ºC.Aliquottoavoidfreeze/thawcycles
ProductStability:Productsarestableforoneyearfrompurchasewhenstoredproperly
ShippingConditions:Shipongelice,storeat-20ºCimmediatelyuponarrival
CautionThisproductisintendedFORRESEARCHUSEONLY,andFORTESTSINVITRO,notforuseindiagnosticortherapeuticproceduresinvolvinghumansoranimals.Itmaycontainhazardousingredients. PleaserefertotheSafetyDataSheets(SDS)foradditionalinformationandproperhandlingprocedures.Disposeproductremaindersaccordingtolocalregulations.Thisdatasheetisasaccurateasreasonablyachievable,butNordic-Mubioacceptsnoliabilityforanyinaccuraciesoromissionsinthisinformation.
References1:KobayashiT,etal.ELOVL2overexpressionenhancestriacylglycerolsynthesisin3T3-L1andF442Acells.FEBSLett.2007Jul10;581(17):3157-63.Epub2007Jun11.2:DeAngelisMM,etal.Cigarettesmoking,CFH,APOE,ELOVL4,andriskofneovascularage-relatedmaculardegeneration.ArchOphthalmol.2007Jan;125(1):49-54.3:VasireddyV,etal.LossoffunctionalELOVL4depletesverylong-chainfattyacids(>or=C28)andtheuniqueomega-O-acylceramidesinskinleADIngtoneonataldeath.HumMolGenet.2007Mar1;16(5):471-82.Epub2007Jan5.4:SridharanS,etal.X-raycrystalstructureofMycobacteriumtuberculosisbeta-ketoacylacylcarrierproteinsynthaseII(mtKasB).JMolBiol.2007Feb16;366(2):469-80.Epub2006Nov7.5:SeitsonenS,etal.AnalysisofvariantsinthecomplementfactorH,theelongationofverylongchainfattyacids-like4andthehemicentin1genesofage-relatedmaculardegenerationintheFinnishpopulation.MolVis.2006Jul20;12:796-801.6:JakobssonA,etal.Fattyacidelongasesinmammals:theirregulationandrolesinmetabolism.ProgLipidRes.2006May;45(3):237-49.Epub2006Mar6.Review.7:PleiteR,etal.Inhibitorsoffattyacidbiosynthesisinsunflowerseeds.JPlantPhysiol.2006Sep;163(9):885-94.Epub2006Feb28.8:KajikawaM,etal.Isolationandfunctionalcharacterizationoffattyaciddelta5-elongasegenefromtheliverwortMarchantiapolymorphaL.FEBSLett.2006Jan9;580(1):149-54.Epub2005Dec6.9:KooAJ,etal.Identificationofaplastidacyl-acylcarrierproteinsynthetaseinArabidopsisanditsroleintheactivationandelongationofexogenousfattyacids.PlantJ.2005Nov;44(4):620-32.10:ZhangK.,etal.A5-bpdeletioninELOVL4isassociatedwithtworelatedformsofautosomaldominantmaculardystrophy.;Nat.Genet.27:89-93(2001).11:EdwardsA.O.,etal;AnovelgeneforautosomaldominantStargardt-likemaculardystrophywithhomologytotheSUR4proteinfamily.;Invest.Ophthalmol.Vis.Sci.42:2652-2663(2001).
ProteinReference(s)
DatabaseName:UniProt
Accessionnumber:Q9GZR5(Human)
SpeciesAccession:Human
SafetyDatasheet(s)forthisproduct:NM_SodiumAzide/wp-content/uploads/SDS/AntibodySDSwithSodiumAzideNoridic-MUbio.pdf
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
1.单克隆抗体的优点:
(1)杂交瘤可以在体外“永久”地存活并传代,只要不发生细胞株的基因突变,就可以不断的生产高特异性、高均一性的抗体.
(2)可以用相对不纯的抗原,获得大量高度特异的、均一的抗体.
(3)由于可能得到“无限量”的均一性抗体,所以适用于以标记抗体为特点的免疫学分析方法,如IRMA和ELISA等.
(4)由于单克隆抗体的高特异性和单一生物学功能,可用于体内的放射免疫显像和免疫导向治疗.
2.单克隆抗体的局限性:
(1)单克隆抗体固定的亲和性和局限的生物活性限制了它的应用范围.由于单克隆抗体不能进行沉淀和凝集反应,所以很多检测方法不能用单克隆抗体完成.
(2)单克隆抗体的反应强度不如多克隆抗体.
(3)制备技术复杂,而且费时费工,所以单克隆抗体的价格也较高.
抗原有两个基本特性,即抗原性和免疫原性。有抗原性的物质不一定有免疫原性,所以由此引出半抗原和完全全抗原,半抗原必须经过经过一定的改造(偶联蛋白载体BSA,OVA或者HSA等大分子物质)方能成为完全。一般而言完全抗原分子量越大(大于10KDa),结构越复杂引起免疫反应的能力也就越强。
抗体就是能与特异性抗原结合的免疫球蛋白,抗体一般分为多克隆抗体和单克隆抗体,多克隆抗体能与抗原的多个表位结合。本篇主要讲述兔来源的多克隆抗体的生产步骤
多抗一般制备流程:完全抗原的准备→兔子的免疫→ 效价检测和终放→抗体亲和纯化→抗体的浓缩和保存。
又由于自然存在的抗原大都存在多个抗原表位,会刺激机体产生多种针对同一抗原的不同抗原表位相应的不同抗体.
一般来说多克隆的阳性率高一些,但出现假阳性的比例也高一些。
其次,察看次目的蛋白的存在形式,有没有多聚体形式及变构形式;
最后,查看多家抗体公司的DATA,看看别人的WB做出来的条带的位置。
根据你说的,特异识别多个组织中的同样大小的条带,我觉得很可能就是你的目的蛋白。
暂无品牌问答